Effect of ozone on vascular endothelial growth factor (VEGF) and related inflammatory cytokines in rats with diabetic retinopathy

T.Y. Xie, W. Yan, J. Lou and X.Y. Chen

Department of Ophthalmology, The First Affiliated Hospital of Xinjiang Medical University, Urumchi, China

Corresponding author: X.Y. Chen
E-mail: xueyichendoc@126.com

Received August 31, 2015
Accepted February 12, 2016
Published May 13, 2016
DOI http://dx.doi.org/10.4238/gmr.15027558

ABSTRACT. The aim of this study was to investigate the effect of ozone on inflammatory cytokines in diabetic retinopathy (DR) rats. Male rats (40) weighing 300-360 g were included in this study. Thirty rats were randomly divided into the model and ozone groups after DR was induced by streptozotocin. Ten rats served as the blank group. After the diabetic models were established for one month, the rats in the ozone group were treated with 50 mg/kg ozone coloclysis for one month (three times a week). After the rats were anesthetized by intraperitoneal injection, blood samples from the abdominal aorta were collected, and the supernatant was obtained by centrifugation. Vascular endothelial growth factor (VEGF) and inflammatory cytokine content in the serum was detected by enzyme linked immunosorbent assay. The values of VEGF, intercellular cell adhesion molecule-1, interleukin-1 beta, tumor necrosis factor-α, and IL-6 were significantly different among the three groups (P < 0.05). The cytokine levels in the model group were higher than those in the blank group (P < 0.05). The level
of each cytokine in the ozone group was higher than that in the blank group. Compared with the model group, the cytokine levels in the ozone group were significantly reduced ($P < 0.05$). Ozone had no effect on the blood glucose of diabetic rats. Treatment with ozone coloclisis may effectively reduce the secretion of VEGF and inflammatory cytokines in diabetic retinopathy rats.

**Key words:** Diabetic retinopathy; Ozone treatment; VEGF; Inflammatory cytokines

**INTRODUCTION**

Diabetic retinopathy (DR) is one of the common microvascular complications of diabetes, and it has become the leading cause of blindness in young adults in developed countries (Zhang et al., 2010; Antonetti et al., 2012). In addition to the early control of blood glucose (UK Prospective Diabetes Study Group, 1998), therapies include laser treatment, vitreous cut surgery, and the use of anti-VEGF in nonproliferative retinopathy and proliferative retinopathy, but the effects are unsatisfactory. A clinical study found that people with diabetes have ‘metabolic memory’. When cells were immersed in a high-glucose environment for a period, the inflammatory cytokines and white blood cells that increased could not recover, and controlling blood glucose did not completely inhibit the inflammation induced by previous high-glucose exposure (Ihnat et al., 2007). Meanwhile, studies also confirmed that the pathological features and development process of DR indicate low-grade chronic inflammation (Adamis, 2002). Research has also shown that the levels of tumor necrosis factor (TNF)-α, interleukin-1 beta (IL-1β), IL-6, and intercellular cell adhesion molecule-1 (ICAM-1) in DR patients’ serum and vitreous retinas were significantly higher than those in non-diabetic patients, and this was positively correlated with the severity of fertile DR (Joussen et al., 2004; Kalstel et al., 2007; Myśliwiec et al., 2008; Aveleira et al., 2010; Wiwanitkit, 2011). Inflammatory cytokines triggered by high-glucose may be one contributing factor to the development of complications related to diabetes under the despite stable control of blood glucose. Hence, blocking the occurrence of metabolic memory through the use of anti-inflammatory and antioxidant agents can delay the development of DR. As early as 1964, Powell and Field (1964) found that patients with arthritis who took anti-inflammatory drugs had less tendency to develop severe diabetes in clinical observations (King, 2008). Because of the non-specific chronic inflammation, however, it is difficult to control the development of DR using anti-inflammatory drugs. Therefore, it is important to find a safer anti-inflammatory agent for the prevention and control of DR.

Ozone is an allotrope made up of three oxygen atoms and is a type of broad-spectrum and high-efficient disinfectant. Its oxidation is extremely strong, and ozone has a very good sterilizing effect; during the Second World War, ozone was widely used for treatment of infection caused by injuries. Further studies have shown that ozone has anti-inflammatory and antioxidant effects, inhibits cell apoptosis, and helps with immune regulation (Calunga et al., 2005; Chen et al., 2008). Ozone can reduce inflammation damage by regulating the...
inflammatory mediators (IL-6, IL-8) and the expression of cytokines (TNF-α) (Di Filippo et al., 2008). The present study aimed to understand the effect of ozone on inflammatory cytokines and as a treatment for DR in a diabetic rat model.

MATERIAL AND METHODS

Animals

Sprague-Dawley (SD) male rats used in this study were provided by the animal experiment center of Xinjiang Medical University [license: SCXK (new) 2003-0001]. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal use protocol has been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the First Affiliated Hospital of Xinjiang Medical University (ethical review number: protocol 09-030).

Establishment of the rat diabetic model

SD male rats (40) (300-360 g) aged 12-16 weeks were fed adaptably for 1 month. Ten rats were randomly selected for the normal control group and fed with normal feed. The remaining rats (30) were fed high fat and glucose feed (15% fat, 18% glucose, 2% egg yolk, 0.2% bile salts, 62.8% normal feed) for 45 days, were fasted but watered after 12 h, and administered 30 mg/kg streptozotocin (STZ, 10 g/L, Sigma company, USA) diluted with sterile fresh citrate buffer (0.1 mM, pH 4.3-4.5) to establish the diabetic rat model via one-time intraperitoneal injection. At 24 h after injection, the blood glucose was detected by taking blood from the tail (SumStep glucosemeter, Johnson & Johnson). An average fasting glucose ≥11.1 mM was considered standard, and rats that did not meet the standard were administered another injection. Rats that still did not meet the standard were removed from the study, and thus, 23 SD rats remained. Rats were weighed and blood glucose was tested regularly.

Grouping

After observing the blood glucose and weight changes for 1 month, the model rats were randomly divided into two groups. The diabetes model control group (N = 11) was not given any intervention. In the ozone treatment group (N = 12), a mixture of ozone (concentration of 50 μg/mL, produced by ozone generating apparatus, Germany) was slowly infused into the rectum, after emptying, at about 0.5 cm, with a dosage of 0.5 mg/kg. The apparatus was pressed against the anus for 5 min to prevent gas emission. The treatment was repeated three times a week, and the course of treatment was one month.

Sampling

After a period of ozone treatment, chloral hydrate (0.3 mL/100 g, 0.5% chloral hydrate) (Department of Pharmaceutical, the First Affiliated Hospital of Xinjiang Medical University) was injected into the abdomens of rats in each group. The eyeballs were removed after anesthesia and were cut along the angle of the sclera edge on ice using a microscope. The front section and
part of the vitreum were removed and the bilateral retinal tissue was stripped rapidly and placed in a freeze pipe, frozen with liquid nitrogen for 10 min, and stored at -80°C. After removing the eyeballs, the belly line was incised, separated bluntly to reveal the abdominal aorta, and the arterial blood was collected. The supernatant was centrifuged at -80°C.

**Measurement with ELISA**

The balanced ELISA Kit (VEGF Rat ELISA Kit (Abcam, Lot: GR148932-1 batch No.: ab100786), ELISA kit for IL-1β (Cloud-Clone Corp; article No.: SEA563Ra; batch No.: L140116385), ICAM-1 Rat Elisa Kit (Abcam, Lot: GR125560-1; batch No.: ab100763), IL-6 Rat Elisa Kit (Lifetech, Lot: 1449842A; batch No.: KRC0061), and TNF-α Rat Elisa Kit (Life technologies, Lot: 1290859B; batch No.: KRC3011) were used to determine cytokine levels. Samples were thawed at room temperature for 30 min and centrifuged (Shanghai Lishen Scientific instrument Co., LTD.; batch No.: Neofuge 15R) at 4°C, 12,000 rpm for 5 min. Samples were diluted to the appropriate concentration. To each well, 100 μL standard or sample was added, and the plate was sealed with a seal membrane. The plate was then shaken on a micro oscillator (Medical instrument factory; Jintan city, model: MM-2) at room temperature for 2.5 h. The membrane was carefully removed and the plate was dried. Subsequently, 300 μL detergent was added to each well, removed after 2 min, and the plate patted dry. This was repeated five times. Then, 100 μL 1X Biotinylated ICAM1 detection antibody was prepared and added to each well. The plate was shaken at room temperature for 1 h, liquid removed, 300 μL detergent added to each well, removed after 2 min, and plate patted dry. This was repeated five times. Then, 100 μL 1X HRP-Streptavidin solution was added to each well, the plate was shaken for 45 min, and the liquid was removed. Again, 300 μL detergent was added to each well, removed after 2 min, and the plate patted dry, repeating five times. TMB One-Step Substrate (100 μL) was added to each well and the plate was shaken away from light for 30 min. Stop solution (50 μL) was added to each well to end the reaction, and the wavelength optical density value (OD value) of each well was determined at 450 nm with a microplate reader (Bio-rad, xMarkTM) after 5 min. The results were processed using ELISA data processing software.

**Statistical analysis**

The SPSS17.0 software was used for the statistical analysis, and the data are reported as means ± SD. The homogeneity test of variance was performed on each sample mean. The expression of each factor in each group was used in the single factor level design analysis of variance. For pairwise comparisons, the LSD t-test was used and groups with heterogeneity of variance were tested using the Dunnett T3 test. P < 0.05 was considered statistically significant.

**RESULTS**

**General health**

After 1 week, SD rats began to exhibit increased drinking, eating, and polyuria. One month later, urine volume decreased, rat weights decreased, and there was an increase in blood glucose (Figure 1). The color of the rat tail began to darken, indicating a state of high blood glucose. The weight and blood glucose levels of the zone and model groups before and after
induction were not significantly different, indicating a successful model (weight: \( t = 1.796, P > 1.796 \); blood glucose \( t = 1.714, P > 1.714 \)). After treatment with ozone, the weight and blood glucose of the two groups was not statistically different (weight: \( t = 0.105, P > 0.105 \); blood glucose: \( t = 1.387, P > 1.387 \)) indicating that the ozone treatment had no effect on blood glucose and weight (Table 1).

**Figure 1.** Changes in rat weight and blood glucose in the model and ozone groups. 1: Before modeling, 2: modeling, 3: one week after modeling, 4: one month after modeling, 5: before sacrifice.

**Table 1.** Changes of blood sugar and weight of rats in model group and ozone group.

<table>
<thead>
<tr>
<th>Time point</th>
<th>Blood sugar (mM)</th>
<th>Weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Model group</td>
<td>Ozone group</td>
</tr>
<tr>
<td>Before modeling</td>
<td>5.14 ± 0.14</td>
<td>4.9 ± 0.49</td>
</tr>
<tr>
<td>Model establishment</td>
<td>17.85 ± 3.21</td>
<td>19.03 ± 3.87</td>
</tr>
<tr>
<td>1 week after modeling</td>
<td>18.28 ± 4.3</td>
<td>23 ± 3.46</td>
</tr>
<tr>
<td>1 month after modeling</td>
<td>22.09 ± 3.3</td>
<td>24.27 ± 2.22</td>
</tr>
<tr>
<td>Sacrifice</td>
<td>21.72 ± 2.54</td>
<td>22.62 ± 2.53</td>
</tr>
</tbody>
</table>

**ELISA**

The inflammatory cytokines presented in different levels in the serum. The 95% confidence intervals of the blank group were 2.51-6.06 pg/mL for VEGF, 74.89-134.14 pg/mL for ICAM-1, 1.97-12.33 pg/mL for TNF-α, 5.54-7.76 pg/mL for IL-1β, and 36.96-51.51 pg/mL for IL-6. Five kinds of inflammatory cytokines between the three groups exhibited significant differences in serum levels (VEGF: \( F = 62.249 \); IL-1β: \( F = 43.00 \); IL-6: \( F = 54.63 \); TNF-α: 58.03; ICAM-1: \( F = 29.75, P < 0.05 \)). Compared with the blank group, each cytokine in the model group was increased (\( P < 0.05 \)), with TNF-α and IL-6 increasing 7.85 and 3.58 times the blank group, respectively (\( P < 0.05 \)) (Figure 2) (Table 2). Compared with the model group, each cytokine level was decreased in the ozone group. IL-6 levels fell nearly 30% (\( P < 0.05 \)), and the levels of VEGF, IL-1β, and IL-6 were close to those of the blank control group. There was no significant difference between the level of IL-6 in the blank and ozone groups (\( P > 0.05 \)).
Figure 2. Expression of related inflammation cytokines in the serum of rats.

Table 2. Expression of related inflammation cytokines in serum of rats (means ± SD).

<table>
<thead>
<tr>
<th>Group</th>
<th>VEGF (pg/mL)</th>
<th>TNF-α (pg/mL)</th>
<th>ICAM-1 (ng/mL)</th>
<th>IL-1β (pg/mL)</th>
<th>IL-6 (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank</td>
<td>4.29 ± 1.11</td>
<td>7.15 ± 3.25</td>
<td>104.51 ± 18.61</td>
<td>6.65 ± 0.69</td>
<td>44.23 ± 4.57</td>
</tr>
<tr>
<td>Model</td>
<td>12.1 ± 1.62*</td>
<td>56.18 ± 11*</td>
<td>317.16 ± 73.84*</td>
<td>17.28 ± 3.71*</td>
<td>158.42 ± 34.57*</td>
</tr>
<tr>
<td>Ozone</td>
<td>4.44 ± 1.76*</td>
<td>29.56 ± 4.4*</td>
<td>142.16 ± 41.99*</td>
<td>7.01 ± 0.78*</td>
<td>52.15 ± 8.07*</td>
</tr>
</tbody>
</table>

*Compared with the blank group, P < 0.001; *Compared with model group, P < 0.001.

DISCUSSION

The pathogenesis of diabetic retinopathy is not fully understood. Animal experiments have shown that retinal blood vessels of diabetic rats induced by STZ show signs of inflammatory response, such as leukocyte adhesion and infiltration, which is intensified throughout the course of the disease (Chibber et al., 2007). Clinical trials have shown that patients with diabetes were in a mild inflammation and stress state, which can cause activation of the body’s immune system, mainly an increase in phagocytes and peripheral lymphocytes, the activation of immune cells in the blood plasma, and an increase in the concentrations of pro-inflammatory cytokines such as PGE2, IL-1β, IL-2, and IL-6. Therefore, researchers have suggested that diabetes is a chronic low-grade inflammatory and autoimmune disease (Doganay et al., 2002). High blood glucose can cause leukocyte adhesion to vascular endothelial cells, resulting in destruction of the blood retinal barrier (BRB), and a high level of TNF-α in blood circulation can be obtained in retinal blood vessels only through crossing the destroyed BRB and inducing the expression of ICAM-1. At the same time, the increasing accumulation of leukocyte adhesion in the capillaries forms small emboli that block capillaries and release a variety of active substances, which aggravate microcirculation, while the hypoxia state of the retina stimulates the expression of VEGF. This upregulates the expression of vascular endothelial adhesion factors (such as ICAM-1) and IL-1β, which further aggravates the
hypoxia state, leading to DR (Doganay et al., 2002), constituting a vicious cycle. There are many inflammatory factors and mediators involved in the development of DR, and they play an important role in the disease prognosis. Thus, preventing inflammation is necessary for controlling the occurrence and development of DR.

Combined with the unsaturated fatty acids in the bacterial cell membranes, ozone can oxidize intracellular enzyme protein, RNA, and DNA, and change the cell permeability, which results in inactivation and the dissolution of dead bacteria. In theory, DR is an ischemia and anoxia disease involving chronic low-grade inflammation. The anti-inflammatory and immune enhancing functions of ozone are relevant to the pathogenesis of DR. A large number of clinical experiments have established that ozone can improve ischemia-reperfusion injury (Stadlbauer et al., 2008), accelerate healing of the diabetic foot (Wainstein et al., 2011), and improve diabetic nephropathy (Morsy et al., 2010). This research focused mainly on exploration of the therapeutic effect of ozone on DR from the angle of inflammatory cytokines.

VEGF is a growth factor that now is closely related to the occurrence and development of DR, and high expression of VEGF can cause pathological changes, such as destruction of the BRB and formation of new blood vessels. Therefore, anti-VEGF therapies can effectively alleviate middle-late DR. In this study, the level of VEGF in the model group was three times higher than that of the blank group and stayed high, which confirmed that the content of VEGF in 2-month STZ rat serum had begun to rise. Noma et al. (2002) showed that a VEGF content that is increased by three times indicates the proliferative DR period. The content of VEGF in the ozone group was lower than that of the model group and the difference was statistically significant, proving that ozone treatment can effectively reduce the expression of VEGF. Hence, ozone can also be considered an anti-VEGF treatment. In this study, VEGF was detected in the blank control group, and a certain amount of VEGF is necessary for blood vessels to maintain normal function (Malone et al., 2001). However, high expression of VEGF can lead to a series of pathological changes. There is controversy regarding whether the level of VEGF in the serum is representative of the content in the retina. There are studies claiming that VEGF of the retina is derived from the retina itself, rather than the circulation of blood (Storkebaum et al., 2004; Semeraro et al., 2014). Our results showed high expression of VEGF in both the retina and serum of 2-month diabetic rats, suggesting that VEGF in the serum does reflect the content of VEGF in the retina to a certain degree.

Leukocyte adhesion to the retinal vasculature is thought to be associated with endothelial cell death, capillary occlusion, and increased vascular permeability, which all contribute to the progression of diabetic retinopathy (Kriegstein and Granger, 2001). Therefore, adhesion molecules play an important role in DR. Previous studies reported that the increased number of adherent leukocytes in the diabetic retina is mediated by the concomitant increase in ICAM-1 expression in the retinal vasculature (Zhang et al., 2009). Therefore, ICAM-1 represents the initiation of vascular lesions in early DR, and it is mutually reinforced by the expression of VEGF. Similar to other reported results, this study also showed that the serum content of ICAM-1 of the model group was three times higher than that of the blank group, confirming that even 2-month diabetic rats had started the process of inflammation with endothelial injuries of the blood capillary. After treatment with ozone, the content of ICAM-1 was slightly higher than that of the blank control group and was far lower than the model group, and there was no statistically significant difference between the ozone treatment group and the blank group. This confirmed that ozone can inhibit the early adhesion of white blood cells in diabetic rat serum, relieve capillary endothelial injury, and block the synergetic effect...
of ICAM-1 and VEGF, which is very important for delaying the development of DR.

TNF-α is a multi-functional inflammatory cytokine produced by mononuclear macrophages, lymphocytes, and endothelial cells (Behl et al., 2008; Gustavsson et al., 2008). TNF-α can cause impairment of vasodilation through nitric oxide (NO) damage, leading to endothelial dysfunction and microvascular lesions. In addition, TNF-α can stimulate stasis of white blood cells, improve permeability of retinal vasculature by directly damaging the BRB, stimulate macrophages and other cells to produce cytokines, such as IL-6 and IL-8, enhance the local inflammatory response in the retina, and increase the expression of VEGF. The results showed that compared with the blank control group, the content of TNF-α increased significantly, but compared with the model group, there was a decrease, showing that ozone can inhibit the release of TNF-α. TNF-α remains an independent determinant factor for PDR (Gustavsson et al., 2008), and ozone inhibits DR via anti-inflammatory actions. Therefore, ozone reducing the content of TNF-α of DM rats can maintain the blood retinal barrier to some extent and decrease the expression of other relevant inflammation cytokines.

IL-1β is a proinflammatory cytokine with bone-marrow-stimulating properties, and it can exacerbate the expression of other cytokines and adhesion molecules (Liu et al., 2012). Similar to previous results (Cassel and Sutterwala, 2010; Vandannvagsar et al., 2011), this study showed that IL-1β could be detected in the peripheral serum of STZ rats in the blank control group. Meanwhile, the level in the model group also increased two times that of the blank group, and after ozone treatment, there was a decrease to close to that of the blank group. Studies have shown that IL-1β cannot be detected in the peripheral blood (Gustavsson et al., 2008), but we showed that even a small amount of IL-1β was detected in the peripheral serum of healthy rats. This could be attributed to the use of different subjects or experimental methods and should be confirmed by further studies. However, this study showed that ozone can reduce the content of IL-1β, reduce the adhesion of leukocytes, protect capillaries, and block inflammatory cytokine release.

IL-6, a proinflammatory cytokine, is a main inductive factor in the acute phase of reaction to infection or trauma. IL-6 has a direct toxic effect on islet cells, accelerating the onset of diabetes (Yuuki et al., 2001; Spranger et al., 2003; Joussen et al., 2004). Concomitantly, under the effect of IL-1 induced by reactive oxygen species (ROS), IL-6 can prompt the expression of ICAM-1, causing further damage to endothelial cells. Cohen et al. (1996) believed that IL-6 had a synergistic effect on IL-1β and TNF-α, and IL-6 can directly induce the expression of VEGF (Ishida et al., 2003), leading to the generation of retinal neovascularization. Thus, IL-6 not only is an important factor in the acute phase of inflammation, but also plays an important role in the subsequent process of low-grade chronic inflammation. The results also showed that the content of IL-6 in the model control group was 3-4 times that of the blank control group, confirming that it was presented as an acute inflammatory process in 2-month DM rat serum. After treatment with ozone, the content of IL-6 in the rat serum was 8 pg/mL higher than that of the blank control group, and significantly lower than the model control group, which suggested that ozone can control the expression of IL-6.

Studies have determined that TNF-α can be an independent influence factor in PDR (Gustavsson et al., 2008), and that VEGF is positively related to ICAM-1, IL-1β, and IL-6 (Cohen et al., 1996; Joussen et al., 2002; Ishida et al., 2003; Moore et al., 2003; Chan et al., 2010). Our study had similar results. The cytokine levels were increased in the model group compared to the control, and this was positively correlated with VEGF. Therefore, ozone has an inhibitory effect on other related inflammatory cytokines. The effect of ozone is enhanced by its inhibition of several cytokines, demonstrating why ozone is commonly used as an anti-inflammatory agent.
CONCLUSION

The experiment showed that VEGF and other inflammatory factors in the serum of 2-month rats induced by STZ increased, indicating that the inflammatory response plays a role in the development of DR before clinical manifestations appear explicitly. Inhibition of VEGF and inflammatory mediators with ozone confirmed that ozone decreases the expression of related inflammatory cytokines in the retina and serum of early DM rats, reducing inflammation and halting the development of DR. This research showed that ozone had no influence on blood glucose, while inhibiting inflammatory cytokine release, revealing that the mechanism of ozone is not lowering blood glucose.

The limitations of this study were few samples, short course of treatment (only one course of treatment), and although enema treatment is easy to implement, dosage is not easy to control (Koleva-Georgieva et al., 2011). However, it is clear that ozone indeed inhibited the release of inflammatory mediators in the serum of DM rats. Although many clinicians have concerns about the side effects of ozone, such as respiratory stimulation, when used correctly, ozone is safe. The ozone generator is simple to operate, and it is low-cost and readily available, making it an ideal treatment for patients with DR in developing countries. Ozone has been used for the treatment of hypoxic-ischemic disease, ischemic-reperfusion injury, age-related macular degeneration, and diabetic foot in many countries with satisfactory results. Thus, the results in this study will provide the foundation for future in vivo experiments, providing further evidence for the value of ozone in the clinic.

Conflicts of interest

The authors declare no conflicts of interest.

ACKNOWLEDGMENTS

Research supported by the Natural Scientific Research Fund Project of Xinjiang Uygur Autonomous Region (#2014211C046).

REFERENCES


Dogany S, Evereklioglu C, Er H, Türköz Y, et al. (2002). Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. *Eye (Lond.)* 16: 163-170. [http://dx.doi.org/10.1038/sj.eye/6700095](http://dx.doi.org/10.1038/sj.eye/6700095)

Gustavsson C, Agardh E, Bengtsson B and Agardh CD (2008). TNF-α is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. *J. Diabetes Complications* 22: 309-316. [http://dx.doi.org/10.1016/j.jdiacomp.2007.03.001](http://dx.doi.org/10.1016/j.jdiacomp.2007.03.001)


Liu Y, Biarnés Costa M and Gerhardinger C (2012). IL-1β is upregulated in the diabetic retina and retinal vessels: cell-specific effect of high glucose and IL-1β autostimulation. *PLoS One* 7: e36949. [http://dx.doi.org/10.1371/journal.pone.0036949](http://dx.doi.org/10.1371/journal.pone.0036949)

Malone JJ, Morrison AD, Pavan PR and Cuthbertson DD; Diabetic Control and Complications Trial (2001). Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years’ duration screened for the diabetes control and complications trial. *Diabetes Care* 24: 522-526. [http://dx.doi.org/10.2337/diacare.24.3.522](http://dx.doi.org/10.2337/diacare.24.3.522)

Moor TS, Moore NC, Kaji Y, Frizzell RA, et al. (2003). The role of advanced glycation end products in retinal microvascular leukostasis. *Invest. Ophthalmol. Vis. Sci.* 44: 4457-4464. [http://dx.doi.org/10.1167/iovs.02-1063](http://dx.doi.org/10.1167/iovs.02-1063)


